Skip to content

Research at St Andrews

Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations

Research output: Contribution to journalArticle

Author(s)

Jeremy C Hobart, Stefan J Cano, John P Zajicek, Alan J Thompson

School/Research organisations

Abstract

Have state-of-the-art clinical trials failed to deliver treatments for neurodegenerative diseases because of shortcomings in the rating scales used? This Review assesses two methodological limitations of rating scales that might help to answer this question. First, the numbers generated by most rating scales do not satisfy the criteria for rigorous measurements. Second, we do not really know which variables most rating scales measure. We use clinical examples to highlight concerns about the limitations of rating scales, examine their underlying rationales, clarify their implications, explore potential solutions, and make some recommendations for future research. We show that improvements in the scientific rigour of rating scales can improve the chances of reaching the correct conclusions about the effectiveness of treatments.

Close

Details

Original languageEnglish
Pages (from-to)1094-105
Number of pages12
JournalLancet Neurology
Volume6
Issue number12
DOIs
Publication statusPublished - Dec 2007

    Research areas

  • Clinical Trials as Topic, Guidelines as Topic, Humans, Neurodegenerative Diseases, Outcome Assessment (Health Care), Treatment Outcome

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Simvastatin as a neuroprotective treatment for Parkinson's disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study

    Carroll, C. B., Webb, D., Stevens, K. N., Vickery, J., Eyre, V., Ball, S., Wyse, R., Webber, M., Foggo, A., Zajicek, J., Whone, A. & Creanor, S., 7 Oct 2019, In : BMJ Open. 9, 10, 11 p., e029740.

    Research output: Contribution to journalArticle

  2. Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis

    Freeman, J. A., Hendrie, W., Jarrett, L., Hawton, A., Barton, A., Dennett, R., Jones, B., Zajicek, J. P. & Creanor, S., 1 Aug 2019, In : Lancet Neurology. 18, 8, p. 736-747

    Research output: Contribution to journalArticle

  3. A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT

    Gunn, H., Andrade, J., Paul, L., Miller, L., Creanor, S., Stevens, K., Green, C., Ewings, P., Barton, A., Berrow, M., Vickery, J., Marshall, B., Zajicek, J. P. & Freeman, J., 1 Jun 2019, In : Health Technology Assessment. 23, 27, p. 1-166

    Research output: Contribution to journalArticle

  4. Machine-learning based identification of undiagnosed dementia in primary care: a feasibility study

    Jammeh, E. A., Carroll, C. B., Pearson, S. W., Escudero, J., Anastasiou, A., Zhao, P., Chenore, T., Zajicek, J. & Ifeachor, E., 12 Jun 2018, In : BJGP Open. 2, 2, 13 p., bjgpopen18X101589.

    Research output: Contribution to journalArticle

  5. Improving the quality of cognitive screening assessments: ACEmobile, an iPad-based version of the Addenbrooke's Cognitive Examination-III

    Newman, C. G. J., Bevins, A. D., Zajicek, J. P., Hodges, J. R., Vuillermoz, E., Dickenson, J. M., Kelly, D. S., Brown, S. & Noad, R. F., 2018, In : Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 10, p. 182-187 6 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis

    Freeman, J. A., Hendrie, W., Jarrett, L., Hawton, A., Barton, A., Dennett, R., Jones, B., Zajicek, J. P. & Creanor, S., 1 Aug 2019, In : Lancet Neurology. 18, 8, p. 736-747

    Research output: Contribution to journalArticle

  2. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): A multicentre, randomised, double-blind extension trial

    Giovannoni, G., Gold, R., Selmaj, K., Havrdova, E., Montalban, X., Radue, E. W., Stefoski, D., McNeill, M., Amaravadi, L., Sweetser, M., Elkins, J. & O'Neill, G., 2014, In : Lancet Neurology. 13, 5, p. 472-481 10 p.

    Research output: Contribution to journalArticle

  3. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

    Zajicek, J., Ball, S., Wright, D., Vickery, J., Nunn, A., Miller, D., Gomez Cano, M., McManus, D., Mallik, S., Hobart, J. & CUPID investigator group, Sep 2013, In : Lancet Neurology. 12, 9, p. 857-65 9 p.

    Research output: Contribution to journalArticle

  4. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial

    Group, UKMND-LALS. S., Apr 2013, In : Lancet Neurology. 12, 4, p. 339-345 7 p.

    Research output: Contribution to journalArticle

ID: 242679756

Top